EPx4 Raises Odds of Renal, Nerve, Hearing Harms - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

  • By

  • Kerri Miller

  • February 25, 2026

  • 5 min

Share

  • 1

    Long-term survivors of testicular cancer treated with EPx4 face higher odds of renal impairment, ototoxicity, and peripheral neuropathy compared to BEPx3.

  • 2

    The study analyzed 798 patients who completed cisplatin-based chemotherapy, with a median follow-up age of 45 years and median time since treatment of 11 years.

  • 3

    Patients receiving EPx4 had 1.55 times the odds of renal impairment and 1.48 times the odds of hearing loss compared to those treated with BEPx3.

  • 4

    41% of patients exhibited reduced eGFR below 90 mL/min/1.73 m², exceeding US population norms, with significant associations to hypertension and cardiovascular disease.

  • 5

    Chemotherapy regimen significantly impacted self-reported global physical health, with BEPx4 and VIPx4 showing the most pronounced reductions in health scores.

Original Source(s)

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

  • by Kerri Miller

  • February 25, 2026

Related Content

FDA Approves Dual-Energy Catheter Ablation Platform

The platform integrates with the CARTO ecosystem and enables physicians to use either pulsed field or radiofrequency energy based on patient anatomy and case complexity.

FDA Approves Subcutaneous Isatuximab-irfc

The approval expands subcutaneous use across newly diagnosed and previously treated multiple myeloma.

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.